Regulator
The FDA issued a discussion paper on robotic medical devices with autonomous or remote control and asked the public for feedback on their benefits and risks.
A regulator's decision
What the source says
“The Food and Drug Administration on Friday issued a discussion paper on robotic medical devices with autonomous or remote teleoperation capabilities and is requesting feedback on the systems’ benefits and risks.”
What it means
A discussion paper is a request for comment, not a rule, so it changes nothing for any robot yet. Our record shows why the question is timely. All ten surgical and medical robots we track sit at stage 5, and the FDA has cleared several of them, including Dexter and da Vinci SP. Those entries show clearances for specific operations, one by one. This paper suggests the FDA is now looking at how much control such systems should have. So far, we hold no record of a rule.
This is a decision by Food and Drug Administration, not news about one robot, so there's no stage on our ladder to show. We include it because rules like this shape which robots can be built, sold and used in surgical and medical.
Written with AI from our stories on Food and Drug Administration and the robots we track in surgical and medical, and checked against them: every figure appears there.
